Yuan Hailong, Chen Gang, Qu Jianhua, Yang Ruixue, Muhashi Maria, Aizezi Gulibadanmu, Jiang Ming
Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi 830054, China.
Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, No. 137 Liyushan South Road, Urumqi 830054, China.
Open Med (Wars). 2021 Oct 5;16(1):1493-1502. doi: 10.1515/med-2021-0368. eCollection 2021.
This study is to investigate the effect of late-onset hemorrhagic cystitis (LOHC) on progression-free survival (PFS) of patients after haploidentical peripheral blood hematopoietic stem cell transplantation (haplo-PBSCT).
This retrospective study enrolled 74 patients with hematological malignancies treated with a myeloablative conditioning regimen and haplo-PBSCT. The effect of LOHC on PFS was studied in terms of HC occurrence, grade, disease type, duration, onset time, gender, and age.
There were 28 patients with LOHC, and no case was with early-onset HC. The cumulative incidence of LOHC was 37.8% (95% CI: 26.9-48.7%). The 2-year expected PFS of 74 patients and 34 AML patients was not significantly different between LOHC patients and patients without HC ( > 0.05). Among 27 ALL patients, the 2-year expected PFS of LOHC patients was 75%, significantly higher than patients without HC (54.2%) ( < 0.05). The 2-year expected PFSs of patients with mild LOHC and severe LOHC were 69.8 and 77.8%, respectively ( > 0.05). Similarly, the onset time, duration, age, and gender of LOHC patients did not show significant effects on PFS ( > 0.05).
After haplo-PBSCT, LOHC has a significant effect on the PFS of ALL patients. The HC grade, duration, onset time, gender, and age have no significant effect on PFS.
本研究旨在探讨迟发性出血性膀胱炎（LOHC）对单倍体相合外周血造血干细胞移植（haplo - PBSCT）后患者无进展生存期（PFS）的影响。
本回顾性研究纳入了74例接受清髓性预处理方案及haplo - PBSCT治疗的血液系统恶性肿瘤患者。从出血性膀胱炎（HC）的发生情况、分级、疾病类型、持续时间、发病时间、性别和年龄等方面研究LOHC对PFS的影响。
有28例患者发生LOHC，无早发性HC病例。LOHC的累积发生率为37.8%（95%CI：26.9 - 48.7%）。74例患者及34例急性髓系白血病（AML）患者中，LOHC患者与无HC患者的2年预期PFS无显著差异（P>0.05）。在27例急性淋巴细胞白血病（ALL）患者中，LOHC患者的2年预期PFS为75%，显著高于无HC患者（54.2%）（P<0.05）。轻度LOHC和重度LOHC患者的2年预期PFS分别为69.8%和77.8%（P>0.05）。同样，LOHC患者的发病时间、持续时间、年龄和性别对PFS均无显著影响（P>0.05）。
haplo - PBSCT后，LOHC对ALL患者的PFS有显著影响。HC分级、持续时间、发病时间、性别和年龄对PFS无显著影响。
